Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31008908 | 0.91 | DRD2 (0.46) | DRD2DRD3TGFBR1MAPTRAB9A | |
| SCHEMBL31205816 | 0.91 | DRD2 (0.40) | DRD2DRD3TGFBR1MAPTRAB9A | |
| SCHEMBL31206080 | 0.78 | DRD2 (0.49) | DRD2DRD3TGFBR1KDM1AMAOB | |
| SCHEMBL2390523 | 0.78 | DRD2 (0.49) | DRD2DRD3KDM1AMAOBNAMPT | |
| SCHEMBL25039624 | 0.78 | DRD2 (0.49) | DRD2DRD3TGFBR1KDM1AMAOB | |
| SCHEMBL25039653 | 0.78 | DRD2 (0.49) | DRD2DRD3TGFBR1KDM1AMAOB | |
| SCHEMBL2390531 | 0.78 | DRD2 (0.49) | DRD2DRD3KDM1AMAOBNAMPT | |
| SCHEMBL1849163 | 0.78 | DRD2 (0.56) | DRD2DRD3KDM1AMAOB | |
| SCHEMBL1849161 | 0.78 | DRD2 (0.56) | DRD2DRD3KDM1AMAOB | |
| SCHEMBL31206158 | 0.77 | DRD2 (0.47) | DRD2DRD3KDM1AMAOBNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | DRD2 4708/4885DRD3 4809/4885TGFBR1 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.